Please login to the form below

simvastatin

This page shows the latest simvastatin news and features for those working in and with pharma, biotech and healthcare.

ezetimibe) and sister product Vytorin (ezetimibe plus simvastatin) - into a blockbuster franchise.

Merck & Co's anacetrapib data fails to generate much excitement

selling Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin) in this therapeutic area despite a small effect on cardiovascular outcomes.
FDA panel rejects cardiovascular outcomes claim for Vytorin

IMPROVE-IT involved 18, 000 high-risk patients with acute coronary syndromes (ACS) - including unstable angina and heart attacks - and compared Vytorin (ezetimibe and simvastatin) to simvastatin alone for their ability ... median seven-year follow-up
Merck hopes for another Keytruda with new immunotherapy deal

But Merck has been hit by the on-going erosion to its cardiovascular and cholesterol drugs Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin).
Relief as study finds no cardiovascular risk with Januvia

Overall pharma sales fell 2% on the back of declines for cholesterol drugs Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin) as well as immunotherapeutic Remicade (infliximab) which is facing biosimilar competition in
Merck's ezetimibe has 'modest' benefit when added to statins

The IMPROVE-IT trial was designed to compare the effects of Vytorin (simvastatin and ezetimibe) versus Zocor (simvastatin) on cardiovascular complications and death in 18, 000 post-ACS patients and got

More from news
Approximately 4 fully matching, plus 43 partially matching documents found.

Rise of generic medicines in Portugal

Pedro Pita Barros, professor of economics and Nova School of Business and Economics, told PME: “Patients have largely benefited from price decreases (for example, simvastatin dropped from above 50 for a ... Generics bestsellers in volume. Simvastatin.